134 related articles for article (PubMed ID: 26592309)
1. The unexpected benefits of the national piperacillin/tazobactam shortage on antibiotic stewardship.
Cunha BA
Infect Dis (Lond); 2016 Apr; 48(4):328-329. PubMed ID: 26592309
[No Abstract] [Full Text] [Related]
2. [In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
Yamada H; Takahata M; Minami S
Jpn J Antibiot; 2002 Feb; 55(1):61-6. PubMed ID: 11977921
[TBL] [Abstract][Full Text] [Related]
3. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections.
Mendez MN; Gibbs L; Jacobs RA; McCulloch CE; Winston L; Guglielmo BJ
Pharmacotherapy; 2006 Jan; 26(1):61-7. PubMed ID: 16509027
[TBL] [Abstract][Full Text] [Related]
4. A 9-Year retrospective review of antibiotic cycling in a surgical intensive care unit.
Sarraf-Yazdi S; Sharpe M; Bennett KM; Dotson TL; Anderson DJ; Vaslef SN
J Surg Res; 2012 Aug; 176(2):e73-8. PubMed ID: 22445457
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Sutherland CA; Nicolau DP
Clin Ther; 2015 Jul; 37(7):1564-71. PubMed ID: 26088525
[TBL] [Abstract][Full Text] [Related]
6. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?
Kundrapu S; Sunkesula VC; Jury LA; Cadnum JL; Nerandzic MM; Musuuza JS; Sethi AK; Donskey CJ
BMC Infect Dis; 2016 Apr; 16():159. PubMed ID: 27091232
[TBL] [Abstract][Full Text] [Related]
7. Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
Pournaras S; Ikonomidis A; Neou E; Kantzanou M; Maniatis AN; Tsakris A
J Antimicrob Chemother; 2008 Mar; 61(3):757-8. PubMed ID: 18199562
[No Abstract] [Full Text] [Related]
8. The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical Centers.
Gross AE; Johannes RS; Gupta V; Tabak YP; Srinivasan A; Bleasdale SC
Clin Infect Dis; 2017 Aug; 65(4):613-618. PubMed ID: 28444166
[TBL] [Abstract][Full Text] [Related]
9. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea.
Wilcox MH; Freeman J; Fawley W; MacKinlay S; Brown A; Donaldson K; Corrado O
J Antimicrob Chemother; 2004 Jul; 54(1):168-72. PubMed ID: 15163654
[TBL] [Abstract][Full Text] [Related]
10. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
11. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
[TBL] [Abstract][Full Text] [Related]
12. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
Baines SD; Freeman J; Wilcox MH
J Antimicrob Chemother; 2005 Jun; 55(6):974-82. PubMed ID: 15860551
[TBL] [Abstract][Full Text] [Related]
13. [In vitro synergistic effects of tazobactam/piperacillin with various antibiotics].
Nishida K; Niidome K; Hashimoto M; Otsuki M; Nishino T
Jpn J Antibiot; 1994 Oct; 47(10):1348-62. PubMed ID: 7807695
[TBL] [Abstract][Full Text] [Related]
14. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
Thabit AK; Grupper M; Nicolau DP; Kuti JL
J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
[TBL] [Abstract][Full Text] [Related]
15. Rationale and evidence for extended infusion of piperacillin-tazobactam.
Kaufman SE; Donnell RW; Hickey WS
Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis.
Pathengay A; Mathai A; Shah GY; Ambatipudi S
J Cataract Refract Surg; 2010 Dec; 36(12):2210-1. PubMed ID: 21111328
[No Abstract] [Full Text] [Related]
17. [Pharmacological properties and clinical efficacies of tazobactam/piperacillin (Zosyn 2.25, Zosyn 4.5), an injectable antibiotic combined with beta-lactamase inhibitor].
Uji T; Hashimoto Y
Nihon Yakurigaku Zasshi; 2009 Jun; 133(6):351-8. PubMed ID: 19521033
[No Abstract] [Full Text] [Related]
18. Cerebral abscess due to Serratia marcescens.
Patra S; Bhat Y R; Lewis LE; Purakayastha J; Sivaramaraju VV
Indian J Pediatr; 2015 Feb; 82(2):199-200. PubMed ID: 25056716
[No Abstract] [Full Text] [Related]
19. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance.
Bantar C; Vesco E; Heft C; Salamone F; Krayeski M; Gomez H; Coassolo MA; Fiorillo A; Franco D; Arango C; Duret F; Oliva ME
Antimicrob Agents Chemother; 2004 Feb; 48(2):392-5. PubMed ID: 14742186
[TBL] [Abstract][Full Text] [Related]
20. Effective use of a clinical decision-support system to advance antimicrobial stewardship.
Patel J; Esterly JS; Scheetz MH; Bolon MK; Postelnick MJ
Am J Health Syst Pharm; 2012 Sep; 69(18):1543-4. PubMed ID: 22935933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
